ATE397959T1 - Verwendung von erbb-rezeptorliganden zur behandlung von diabetes - Google Patents

Verwendung von erbb-rezeptorliganden zur behandlung von diabetes

Info

Publication number
ATE397959T1
ATE397959T1 AT00921827T AT00921827T ATE397959T1 AT E397959 T1 ATE397959 T1 AT E397959T1 AT 00921827 T AT00921827 T AT 00921827T AT 00921827 T AT00921827 T AT 00921827T AT E397959 T1 ATE397959 T1 AT E397959T1
Authority
AT
Austria
Prior art keywords
erbb receptor
receptor ligands
methods
treat diabetes
mammals
Prior art date
Application number
AT00921827T
Other languages
English (en)
Inventor
Xiaojian Huang
Timothy Stewart
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE397959T1 publication Critical patent/ATE397959T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
AT00921827T 1999-04-06 2000-04-05 Verwendung von erbb-rezeptorliganden zur behandlung von diabetes ATE397959T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12801799P 1999-04-06 1999-04-06

Publications (1)

Publication Number Publication Date
ATE397959T1 true ATE397959T1 (de) 2008-07-15

Family

ID=22433188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921827T ATE397959T1 (de) 1999-04-06 2000-04-05 Verwendung von erbb-rezeptorliganden zur behandlung von diabetes

Country Status (12)

Country Link
US (2) US20060029605A1 (de)
EP (1) EP1165113B1 (de)
JP (1) JP4794049B2 (de)
AT (1) ATE397959T1 (de)
AU (1) AU4209300A (de)
CA (1) CA2368017A1 (de)
DE (1) DE60039160D1 (de)
DK (1) DK1165113T3 (de)
ES (1) ES2307505T3 (de)
IL (2) IL145674A0 (de)
PT (1) PT1165113E (de)
WO (1) WO2000059525A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101090732A (zh) * 2004-08-06 2007-12-19 谷柔派普有限公司 治疗糖尿病的方法
CA2609728A1 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
SG10201405107YA (en) * 2006-02-23 2014-10-30 Viacyte Inc Compositions and methods useful for culturing differentiable cells
RU2009128237A (ru) 2006-12-22 2011-01-27 Новеликс Терапьютикс Гмбх (At) Лечение диабета, по меньшей мере, одним антителом, специфичным к рецептору эпидермального фактора роста, или его производным
CN101735346B (zh) 2008-11-07 2012-05-30 中国石油天然气股份有限公司 一种丙烯均聚和共聚的催化剂及其制备方法和应用
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
RU2675928C2 (ru) * 2013-02-06 2018-12-25 Виасайт, Инк. Композиции клеток, полученные из дедифференцированных перепрограммированных клеток
US20160175401A1 (en) * 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
KR102027750B1 (ko) * 2018-05-03 2019-10-02 연세대학교 산학협력단 당 배출용 조성물
WO2021002645A1 (ko) * 2019-07-01 2021-01-07 연세대학교 산학협력단 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
KR102109385B1 (ko) * 2019-08-21 2020-05-12 연세대학교 산학협력단 당 배출용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
EP1466618B1 (de) * 1994-01-24 2009-06-03 The General Hospital Corporation Behandlung von Diabetes
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
JP3945846B2 (ja) * 1995-11-09 2007-07-18 武田薬品工業株式会社 膵臓機能改善剤
US6232288B1 (en) * 1995-11-09 2001-05-15 Takeda Chemical Industries, Ltd. Composition for improving pancreatic function
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
JP4794049B2 (ja) 2011-10-12
EP1165113A2 (de) 2002-01-02
JP2002541117A (ja) 2002-12-03
EP1165113B1 (de) 2008-06-11
ES2307505T3 (es) 2008-12-01
IL145674A0 (en) 2002-06-30
PT1165113E (pt) 2008-09-23
DK1165113T3 (da) 2008-09-08
CA2368017A1 (en) 2000-10-12
AU4209300A (en) 2000-10-23
US20060029605A1 (en) 2006-02-09
IL145674A (en) 2010-12-30
DE60039160D1 (de) 2008-07-24
WO2000059525A3 (en) 2001-02-08
US20080031880A1 (en) 2008-02-07
WO2000059525A2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
ATE212230T1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
DE60329756D1 (de) Mitotische kinesin-hemmer
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
DE60122337D1 (de) Verwendung von taci als antitumormittel
DK0804479T3 (da) Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF
DE60025905D1 (de) In vitro methode zur synchronisation von oozytenreifung
SE0203594D0 (sv) Method for treatment of wood chips
DE60234862D1 (de) Verfahren zur herstellung menschlicher beta-zelllinien
MXPA01008657A (es) Aumento de la proporcion de implante por esterol que activa la meiosis.
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
DE60132466D1 (de) Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
BR9807980A (pt) Uso de um composto e composto para tratar um mamìfero com disfunção cognitiva
ZA202305986B (en) Method for in vitro tissue culture, propagation and preservation of huperzia serrate (thunb) trev.
SE0301917D0 (sv) Methods for identifying active compounds
ATE535246T1 (de) Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165113

Country of ref document: EP